[8-K] Medtronic plc Reports Material Event

Rhea-AI Filing Summary

Medtronic plc filed a current report to announce that it released its financial results for the second quarter of its fiscal year 2026. On November 18, 2025, the company issued a press release with these results, which is included as Exhibit 99.1. The report also confirms Medtronic’s status as an Irish public limited company and lists its ordinary shares and various series of senior notes, with maturities ranging from 2027 to 2053, as being listed on the New York Stock Exchange.

0001613103H91 VY19false00016131032025-11-182025-11-180001613103mdt:A1.125SeniorNotesDue2027Member2025-11-182025-11-180001613103mdt:A0.375SeniorNotesDue2028Member2025-11-182025-11-180001613103mdt:A3.000SeniorNotesDue2028Member2025-11-182025-11-180001613103mdt:A3.650SeniorNotesDue2029Member2025-11-182025-11-180001613103mdt:A2.950SeniorNotesDue2030Member2025-11-182025-11-180001613103mdt:A1.625SeniorNotesDue2031Member2025-11-182025-11-180001613103mdt:A1.000SeniorNotesDue2031Member2025-11-182025-11-180001613103mdt:A3.125SeniorNotesDue2031Member2025-11-182025-11-180001613103mdt:A0.750SeniorNotesDue2032Member2025-11-182025-11-180001613103mdt:A3.375SeniorNotesDue2034Member2025-11-182025-11-180001613103mdt:A3.875SeniorNotesDue2036Member2025-11-182025-11-180001613103mdt:A2.250SeniorNotesDue2039Member2025-11-182025-11-180001613103mdt:A1.500SeniorNotesDue2039Member2025-11-182025-11-180001613103mdt:A1.375SeniorNotesDue2040Member2025-11-182025-11-180001613103mdt:A4.150SeniorNotesDue2043Member2025-11-182025-11-180001613103mdt:A4.200SeniorNotesDue2045Member2025-11-182025-11-180001613103mdt:A1.750SeniorNotesDue2049Member2025-11-182025-11-180001613103mdt:A1.625SeniorNotesDue2050Member2025-11-182025-11-180001613103mdt:A4.150SeniorNotesDue2053Member2025-11-182025-11-18

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________________ 

FORM 8-K

 _____________________________ 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 18, 2025

 _____________________________ 

Medtronic plc

(Exact name of Registrant as Specified in its Charter)

  _____________________________ 

 

Ireland

1-36820

98-1183488

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

Building Two

Parkmore Business Park West

Galway, Ireland

(Address of principal executive offices) (Zip Code)

+353 1 438-1700

(Registrant’s telephone number, including area code)

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol			Name of each exchange on which registered
Ordinary shares, par value $0.0001 per share			MDT			New York Stock Exchange
1.125% Senior Notes due 2027			MDT/27			New York Stock Exchange
0.375% Senior Notes due 2028			MDT/28			New York Stock Exchange
3.000% Senior Notes due 2028			MDT/28A			New York Stock Exchange
3.650% Senior Notes due 2029			MDT/29			New York Stock Exchange
2.950% Senior Notes due 2030			MDT/30			New York Stock Exchange
1.625% Senior Notes due 2031			MDT/31			New York Stock Exchange
1.000% Senior Notes due 2031			MDT/31A			New York Stock Exchange
3.125% Senior Notes due 2031			MDT/31B			New York Stock Exchange
0.750% Senior Notes due 2032			MDT/32			New York Stock Exchange
3.375% Senior Notes due 2034			MDT/34			New York Stock Exchange
3.875% Senior Notes due 2036			MDT/36			New York Stock Exchange
2.250% Senior Notes due 2039			MDT/39A			New York Stock Exchange
1.500% Senior Notes due 2039			MDT/39B			New York Stock Exchange
1.375% Senior Notes due 2040			MDT/40A			New York Stock Exchange
4.150% Senior Notes due 2043			MDT/43A			New York Stock Exchange
4.200% Senior Notes due 2045			MDT/45			New York Stock Exchange
1.750% Senior Notes due 2049			MDT/49			New York Stock Exchange
1.625% Senior Notes due 2050			MDT/50			New York Stock Exchange
4.150% Senior Notes due 2053			MDT/53			New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition

On November 18, 2025, Medtronic plc, a public limited company organized under the laws of Ireland, issued a press release announcing its second quarter fiscal year 2026 financial results. A copy of the press release is furnished as Exhibit 99.1 to this report.

Item 9.01. Exhibits.

(d) List of Exhibits

Exhibit Number						Description
99.1						Press release of Medtronic plc, dated November 18, 2025
104						Cover Page Interactive Data File (embedded with the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Medtronic plc

By

/s/ Thierry Piéton

Date: November 18, 2025

Thierry Piéton

Executive Vice President and Chief Financial Officer (Principal Financial Officer)

EXHIBIT INDEX

Exhibit Number						Description
99.1						Press release of Medtronic plc, dated November 18, 2025
104						Cover Page Interactive Data File (embedded with the Inline XBRL document).

FAQ

What did Medtronic (MDT) announce in this Form 8-K?

Medtronic plc reported that on November 18, 2025, it issued a press release announcing its second quarter fiscal year 2026 financial results, furnished as Exhibit 99.1.

Which financial period does this Medtronic (MDT) 8-K relate to?

The report relates to Medtronic’s second quarter of fiscal year 2026, for which financial results are described in the press release attached as Exhibit 99.1.

What exhibits are included with this Medtronic (MDT) 8-K filing?

The filing includes Exhibit 99.1, which is the press release dated November 18, 2025, and Exhibit 104, the Cover Page Interactive Data File embedded in the Inline XBRL document.

Who signed this Medtronic (MDT) Form 8-K?

The Form 8-K was signed on behalf of Medtronic plc by Thierry Piéton, Executive Vice President and Chief Financial Officer, who serves as the principal financial officer.

Where is Medtronic plc incorporated and headquartered?

Medtronic plc is organized under the laws of Ireland, with its principal executive offices located at Building Two, Parkmore Business Park West, Galway, Ireland.

Which Medtronic (MDT) securities are listed on the New York Stock Exchange?

Medtronic lists its ordinary shares (MDT) and multiple series of senior notes on the New York Stock Exchange, with maturities from 2027 through 2053.